Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Buhrman

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Oncoimmunology|June 5, 2013
Mimotope vaccine efficacy gets a "boost" from native tumor antigensJonathan D Buhrman, Jill E Slansky
Immunologic Research|September 1, 2012
Improving T cell responses to modified peptides in tumor vaccinesJonathan D Buhrman, Jill E Slansky
Journal of Pharmaceutical and Biomedical Analysis|March 7, 2000
Quantitative determination of an extremely polar compound allantoin in human urine by LC-MS/MS based on the separation on a polymeric amino columnA Berthemy, J Newton, D Wu, et al.
Veterinary Microbiology|July 1, 1991
Biological properties of RB51; a stable rough strain of Brucella abortusG G Schurig, R M Roop, T Bagchi, et al.
Cancer Research|November 20, 2012
Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigensJonathan D Buhrman, Kimberly R Jordan, Lance U'ren, et al.
Rapid Communications in Mass Spectrometry : RCM|February 21, 1998
High throughput liquid chromatography/mass spectrometry bioanalysis using 96-well disk solid phase extraction plate for the sample preparationH Simpson, A Berthemy, D Buhrman, et al.
The Journal of Biological Chemistry|October 10, 2013
Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptorJonathan D Buhrman, Kimberly R Jordan, Daniel J Munson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 3, 2016
Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer ModelKatherine A Waugh, Sonia M Leach, Brandon L Moore, et al.
Cancer Immunology, Immunotherapy : CII|February 22, 2012
TCR hypervariable regions expressed by T cells that respond to effective tumor vaccinesKimberly R Jordan, Jonathan D Buhrman, Jonathan Sprague, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 2, 2021
Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancerPengcheng Wei, Kimberly R Jordan, Jonathan D Buhrman, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Oncoimmunology|June 5, 2013
Mimotope vaccine efficacy gets a "boost" from native tumor antigensJonathan D Buhrman, Jill E Slansky
Immunologic Research|September 1, 2012
Improving T cell responses to modified peptides in tumor vaccinesJonathan D Buhrman, Jill E Slansky
Journal of Pharmaceutical and Biomedical Analysis|March 7, 2000
Quantitative determination of an extremely polar compound allantoin in human urine by LC-MS/MS based on the separation on a polymeric amino columnA Berthemy, J Newton, D Wu, et al.
Veterinary Microbiology|July 1, 1991
Biological properties of RB51; a stable rough strain of Brucella abortusG G Schurig, R M Roop, T Bagchi, et al.
Cancer Research|November 20, 2012
Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigensJonathan D Buhrman, Kimberly R Jordan, Lance U'ren, et al.
Rapid Communications in Mass Spectrometry : RCM|February 21, 1998
High throughput liquid chromatography/mass spectrometry bioanalysis using 96-well disk solid phase extraction plate for the sample preparationH Simpson, A Berthemy, D Buhrman, et al.
The Journal of Biological Chemistry|October 10, 2013
Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptorJonathan D Buhrman, Kimberly R Jordan, Daniel J Munson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 3, 2016
Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer ModelKatherine A Waugh, Sonia M Leach, Brandon L Moore, et al.
Cancer Immunology, Immunotherapy : CII|February 22, 2012
TCR hypervariable regions expressed by T cells that respond to effective tumor vaccinesKimberly R Jordan, Jonathan D Buhrman, Jonathan Sprague, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 2, 2021
Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancerPengcheng Wei, Kimberly R Jordan, Jonathan D Buhrman, et al.
Pageof 1